Adoptive transfer of ex vivo expanded autologous tumor-infiltrating lymphocytes together followed by one to two cycles of high-dose IL-2 therapy has emerged in multiple Phase II clinical trials to be one of the most powerful therapies for unresectable metastatic melanoma [1]–[4]. The gene discussed is IL2; the disease is neoplasm.